MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 

Location: Categories / Finance & Investment / Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.
Old Articles: <Older 25961-25970 Newer>
The Motley Fool
September 7, 2007
Michael Leibert
Dueling Fools: SYSCO Bull Rebuttal The bulls feel that SYSCO's dominance and maturity in the food distribution industry is no detriment to the growth opportunities available to it in this huge and highly fragmented business. mark for My Articles 65 similar articles
The Motley Fool
September 7, 2007
Ryan Fuhrmann
Dueling Fools: SYSCO Bear Rebuttal The bears contend that although SYSCO is a profitable and dominant player in the food distribution industry, there are growing concerns about the company's future. mark for My Articles 42 similar articles
The Motley Fool
September 7, 2007
Michael Leibert
Dueling Fools: SYSCO Bull Bulls site SYSCO's strength, stability, and superiority as reasons why this stock could anchor shaky portfolios, and why now may be a good time to buy. mark for My Articles 59 similar articles
The Motley Fool
September 7, 2007
Billy Fisher
Epic Vioxx Victory for Merck Merck scores a major victory in its Vioxx saga in the courtroom as New Jersey's Supreme Court rules against the possibility of a national class action Vioxx lawsuit. Shares react positively. mark for My Articles 244 similar articles
The Motley Fool
September 7, 2007
Steven Mallas
Campbell's Earnings Cool Down Campbell's fourth-quarter income cools; investors, should you sell? mark for My Articles 123 similar articles
The Motley Fool
September 7, 2007
David Lee Smith
Hovnanian's Losing Streak Continues With its third-quarter results, big builder Hovnanian appears to be saying that things could get worse before they improve. Management plans to slash the prices on homes across the country. mark for My Articles 520 similar articles
The Motley Fool
September 7, 2007
Brian Orelli
Clinical Data Gets Personal Clinical Data's lead compound Vilazodone posts strong phase 3 results. The company is searching for common genetic markers among patients who responded positively to the drug. mark for My Articles 428 similar articles
The Motley Fool
September 7, 2007
Anders Bylund
National Turns Up the Heat: Fool by Numbers The fast facts about National Semiconductor's first-quarter results. Sales are down due to the challenging conditions facing cell phone manufacturers. mark for My Articles 2166 similar articles
Financial Advisor
September 2007
Eric Uhlfelder
Broader Horizons Can Pay Off We look at some of the best buys among the growing list of industry-leading foreign companies. mark for My Articles 23 similar articles
The Motley Fool
September 6, 2007
Lawrence A. Rothman
Slow and Steady at J.C. Penney A calendar glitch made the back-to-school season look worse than it really was. Investors, take note. mark for My Articles 277 similar articles
<Older 25961-25970 Newer>    Return to current articles.